Limits...
Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C - Oncotarget (2015)

Bottom Line: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001).Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003).Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

View Article: PubMed Central - PubMed

Affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.

ABSTRACT

Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

No MeSH data available.


Related in: MedlinePlus

Serum FSIP1 expression levels in breast cancers(A) There was no significant difference in serum FSIP1 levels before and after breast cancer surgery in 122 patients (p = 0.162). Serum FSIP1 levels in patients with primary breast cancer were significantly higher than that in patients with benign disease (p < 0.0001). Serum FSIP1 levels in 112 patients with recurrent and metastatic breast cancer were significantly higher than those of patients with primary breast cancer (p = 0.003). (B) The level of FSIP1 was correlated to clinical stages of breast cancer. Serum levels of FSIP1 between stage 0 and stage II cancers were significantly different (stage 0 vs. stage II: p = 0.0314). (C) FSIP1 levels in breast cancer patients with ER- or PR-positive expression were significantly higher than those with ER- or PR-negative expression (p = 0.0018 and p < 0.0001, respectively).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496383&req=5

Figure 2: Serum FSIP1 expression levels in breast cancers(A) There was no significant difference in serum FSIP1 levels before and after breast cancer surgery in 122 patients (p = 0.162). Serum FSIP1 levels in patients with primary breast cancer were significantly higher than that in patients with benign disease (p < 0.0001). Serum FSIP1 levels in 112 patients with recurrent and metastatic breast cancer were significantly higher than those of patients with primary breast cancer (p = 0.003). (B) The level of FSIP1 was correlated to clinical stages of breast cancer. Serum levels of FSIP1 between stage 0 and stage II cancers were significantly different (stage 0 vs. stage II: p = 0.0314). (C) FSIP1 levels in breast cancer patients with ER- or PR-positive expression were significantly higher than those with ER- or PR-negative expression (p = 0.0018 and p < 0.0001, respectively).

Mentions: There was no significant difference in serum FSIP1 levels before and after surgery in the 122 patients with primary breast cancer (4, 637 ± 3, 276 pg/ml vs. 4, 713 ± 3, 065 pg/ml, p = 0.162; Figure 2). However, serum FSIP1 level was significantly higher in patients with primary breast cancer than in patients with benign cancer (4, 713 ± 3, 065 pg/ml vs. 1, 798 ± 1, 943 pg/ml, p = 0.001). Serum FSIP1 level in the 112 patients with recurrent or metastatic breast cancer was also much higher than those of the patients with primary breast cancer (7, 713 ± 3, 065 pg/ml vs. 4, 713 ± 3, 065 pg/ml, p = 0.003; Figure 2A).


Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C - Oncotarget (2015)

Serum FSIP1 expression levels in breast cancers(A) There was no significant difference in serum FSIP1 levels before and after breast cancer surgery in 122 patients (p = 0.162). Serum FSIP1 levels in patients with primary breast cancer were significantly higher than that in patients with benign disease (p < 0.0001). Serum FSIP1 levels in 112 patients with recurrent and metastatic breast cancer were significantly higher than those of patients with primary breast cancer (p = 0.003). (B) The level of FSIP1 was correlated to clinical stages of breast cancer. Serum levels of FSIP1 between stage 0 and stage II cancers were significantly different (stage 0 vs. stage II: p = 0.0314). (C) FSIP1 levels in breast cancer patients with ER- or PR-positive expression were significantly higher than those with ER- or PR-negative expression (p = 0.0018 and p < 0.0001, respectively).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496383&req=5

Figure 2: Serum FSIP1 expression levels in breast cancers(A) There was no significant difference in serum FSIP1 levels before and after breast cancer surgery in 122 patients (p = 0.162). Serum FSIP1 levels in patients with primary breast cancer were significantly higher than that in patients with benign disease (p < 0.0001). Serum FSIP1 levels in 112 patients with recurrent and metastatic breast cancer were significantly higher than those of patients with primary breast cancer (p = 0.003). (B) The level of FSIP1 was correlated to clinical stages of breast cancer. Serum levels of FSIP1 between stage 0 and stage II cancers were significantly different (stage 0 vs. stage II: p = 0.0314). (C) FSIP1 levels in breast cancer patients with ER- or PR-positive expression were significantly higher than those with ER- or PR-negative expression (p = 0.0018 and p < 0.0001, respectively).
Mentions: There was no significant difference in serum FSIP1 levels before and after surgery in the 122 patients with primary breast cancer (4, 637 ± 3, 276 pg/ml vs. 4, 713 ± 3, 065 pg/ml, p = 0.162; Figure 2). However, serum FSIP1 level was significantly higher in patients with primary breast cancer than in patients with benign cancer (4, 713 ± 3, 065 pg/ml vs. 1, 798 ± 1, 943 pg/ml, p = 0.001). Serum FSIP1 level in the 112 patients with recurrent or metastatic breast cancer was also much higher than those of the patients with primary breast cancer (7, 713 ± 3, 065 pg/ml vs. 4, 713 ± 3, 065 pg/ml, p = 0.003; Figure 2A).

Bottom Line: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001).Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003).Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

View Article: PubMed Central - PubMed

Affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.

ABSTRACT

Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

No MeSH data available.


Related in: MedlinePlus